(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Delta Air Lines Beats Estimates; Domino's Pizza Unveils Mixed Results

October 12th, 2023

Delta Air Lines, Inc. (NYSE: DAL) reported third-quarter 2023 earnings of $2.03 per share, beating the consensus EPS estimate of $1.94. The company's quarterly revenue amounted to $15.50 billion, exceeding analysts' projections of $14.54 billion in r. Read more

Breaking: Microsoft Faces IRS Demand for $28.9B in Tax Dispute

October 11th, 2023

In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Microsoft Corporation (Nasdaq: MSFT) disclosed that it has received Notices of Proposed Adjustment (NOPAs) from the Internal Revenue Service (IRS) for the tax years 2004 t. Read more

FTC Proposes Rule to Ban Junk Fees

October 11th, 2023

Proposed rule would prohibit hidden and falsely advertised fee Washington D.C. / CRWE PRESS RELEASE / October 11, 2023 -  The Federal Trade Commission today announced a new proposed rule to prohibit junk fees, which are hidden . Read more

Momentum: Tempest Therapeutics Rides High on TPST-1120 Clinical Data

October 11th, 2023

Shares of Tempest Therapeutics, Inc. (Nasdaq: TPST) surged by more than 400% in pre-market trading due to strong clinical results for TPST-1120 in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma. In a . Read more

UBS' View On Boeing and Northrop Grumman: Unveiling Potential Upsides

October 11th, 2023

UBS has initiated coverage on The Boeing Company (NYSE: BA), one of the most prominent names in the aerospace sector, with a Buy rating and a price target of $275. Closing at $193.53 on Tuesday, this price target presents a noteworthy potential up. Read more

Earnings Reaction Shockwaves: AZZ Rises, e2open Falls

October 10th, 2023

In the latest earnings reports, AZZ Inc. (NYSE: AZZ) has outperformed expectations, reporting second-quarter fiscal 2024 earnings of $1.27 per share. This surpasses the consensus EPS estimate of $1.08. The company's quarterly sales reached $398.50 mi. Read more

France, Germany, Italy, UK, and US Back Israel Amidst Hamas Attacks

October 10th, 2023

Leaders of France, Germany, Italy, the United Kingdom, and the United States have issued a joint statement reaffirming their unwavering support for Israel and condemning Hamas for its acts of terrorism. They stressed that there is never any justifica. Read more

PepsiCo Beats Estimates; NanoString Reveals Upbeat Revenue, Strategic Shift

October 10th, 2023

PepsiCo, Inc. (Nasdaq: PEP) reported third-quarter 2023 earnings of $2.25 per share, surpassing the consensus EPS estimate of $2.15. The company's quarterly sales stood at $23.45 billion, slightly ahead of analysts' expectations of $23.43 billion in . Read more

Applied Digital Beats Estimates; Tigo Energy Sees Below-Consensus Revenue

October 09th, 2023

Applied Digital Corporation (Nasdaq: APLD) reported first-quarter fiscal 2024 adjusted earnings of less than $0.01 per share, beating the consensus estimate loss of $(0.02). The company posted quarterly sales of $36.30 million, exceeding analysts' ex. Read more

Scilex and Oracle: Bullish Views, Potential Upsides Unveiled

October 09th, 2023

HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12. Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $1. Read more